Pimecrolimus Inhibits the Elicitation Phase but Does Not Suppress the Sensitization Phase in Murine Contact Hypersensitivity, in Contrast to Tacrolimus and Cyclosporine A11Results reported in part at the SID meeting 2000 in Chicago (Meingassner J, Fahnrgruber H, Bavandi A: SDZ ASM 981, in contrast to CyA and FK 509, does not suppress the primary immune response in murine allergic contact dermatitis. J Invest Dermatol 114:832, 2000).
- 1 July 2003
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 121 (1) , 77-80
- https://doi.org/10.1046/j.1523-1747.2003.12331.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Pimecrolimus Identifies a Common Genomic Anti-inflammatory Profile, is Clinically Highly Effective in Psoriasis and is Well ToleratedJournal of Investigative Dermatology, 2002
- Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsJournal of the American Academy of Dermatology, 2002
- Macrolactam immunomodulators for topical treatment of inflammatory skin diseasesJournal of the American Academy of Dermatology, 2001
- The Role of CTLA-4 in Murine Contact HypersensitivityJournal of Investigative Dermatology, 2001
- Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506)Journal of Allergy and Clinical Immunology, 2001
- Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized studyBritish Journal of Dermatology, 1999
- A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacologyBritish Journal of Dermatology, 1999
- Dissection of antigenic and irritative effects of epicutaneously applied haptens in mice. Evidence that not the antigenic component but nonspecific proinflammatory effects of haptens determine the concentration-dependent elicitation of allergic contact dermatitis.Journal of Clinical Investigation, 1996
- Systemic Tacrolimus (FK 506) Is Effective for the Treatment of Psoriasis in a Double-blind, Placebo-Controlled StudyArchives of Dermatology, 1996
- Cyclosporine in DermatologyArchives of Dermatology, 1995